You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
Some oncologists said 10 mutations/Mb is an acceptable TMB cutoff in patients who are out of options, while others worry it will drive immunotherapy use in those unlikely to have a lasting benefit.
Health systems' molecular testing labs haven't had to cut back on genomic profiling for cancer patients yet but may need to accommodate COVID-19 testing if needed.
The study showed that patients with targetable genomic markers, especially HER2 alterations, responded well to chemotherapy-free treatments.
With the participation of five cancer centers and clinics, Taproot is hoping to build a national, prospective data registry that is much needed but has been difficult to advance to date.
The company is hoping its technology can help predict which melanoma patients will respond to checkpoint inhibition using immune-related gene expression signals.
Tissue-agnostic drug development approaches have their own set of scientific and financial considerations, but some drugmakers are taking on those challenges.
The approval of two molecularly targeted, tissue-agnostic therapies, has shown researchers that there is a path forward for other pan-cancer markers.
The study researchers further reported that high matching scores predicted both better progression-free and overall survival.
While the study didn't meet its primary endpoint, it showed the potential of transcriptomics to match cancer patients to beneficial treatments.
With sequence data for more than 118,000 tumors profiled at Foundation Medicine, investigators tracked PDL1 amplification prevalence and possible treatment implications.